GURU.Markets stock price, segment price, and overall market index valuation
The company's share price XBIO
Xenetic Biosciences is a biotechnology company with a drug discovery and cell therapy platform. Its stock price reflects both the potential of its own developments and royalties from partners using its technology.
Share prices of companies in the market segment - Cancer cure
Xenetic Biosciences is a biopharmaceutical company developing the XCART platform for creating personalized CAR-T cell therapy for cancer treatment. We've categorized it under "Cancer Treatment." The chart below shows how investors view innovative approaches in immuno-oncology.
Broad Market Index - GURU.Markets
Xenetic Biosciences is a biopharmaceutical company developing a platform for next-generation CAR-T cell therapy. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
XBIO - Daily change in the company's share price XBIO
Xenetic Biosciences, Inc.'s daily price change reflects the extreme volatility inherent in biotech companies. This metric measures sensitivity to news about the development of its cancer drug platform.
Daily change in the price of a set of shares in a market segment - Cancer cure
Xenetic Biosciences is developing the PolyXen platform to improve the pharmacokinetics of biologics, including cancer treatments. This is a highly specialized area of biotechnology. The chart below shows the volatility in this sector, which helps assess how XBIO's risks compare to those of the industry.
Daily change in the price of a broad market stock, index - GURU.Markets
Xenetic Biosciences is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization XBIO
For Xenetic Biosciences, year-over-year performance is a story about its PolyXen drug-improvement platform. Its 12-month market cap depends on progress in applying this technology, as well as its more important program to develop CAR-T therapies for cancer treatment. Success in this area could fundamentally transform the company.
Annual dynamics of market capitalization of the market segment - Cancer cure
As an early-stage biotech, Xenetic is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about its cell therapy platform. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Xenetic Biosciences, a biopharmaceutical company developing the PolyXen platform for improving the performance of biological drugs, is a technology partner for other pharmaceutical companies. Its year-over-year market capitalization reflects its success in securing licensing agreements and advancing its own projects.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization XBIO
Xenetic is a biopharmaceutical company with a platform for developing long-acting drugs. Its monthly performance depends on progress in its clinical programs and on its partnerships with other companies using its PolyXen technology.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Biotech platforms are the foundation for the development of many future drugs, but they require enormous investment in the early stages. The dynamics of this sector, shown in the chart, reflect a high degree of speculative interest. In this environment, companies like Xenetic Biosciences are developing their technologies.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Xenetic Biosciences, a biopharmaceutical company developing cancer therapies, thrives on lab news. Its shares can soar or collapse based on research data, completely ignoring the broader market, as is typical for biotech.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization XBIO
Xenetic Biosciences is developing a platform for creating long-acting drugs, including for cancer treatment. Its weekly stock price reflects progress in applying its technology in partnership with other companies, as well as clinical trial results.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Xenetic Biosciences is developing the PolyXen platform to improve the performance of biologics. Its business model involves partnerships with other pharmaceutical companies. This chart shows how news of these partnerships impacts the company's stock relative to overall biotech trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Xenetic Biosciences is developing a platform for improving drugs. Its business model involves partnerships with other pharmaceutical companies. This chart shows how news of these partnerships impacts the company's stock price compared to overall trends.
Market capitalization of the company, segment and market as a whole
XBIO - Market capitalization of the company XBIO
Xenetic Biosciences' market capitalization is a measure of investor valuation of its PolyXen technology platform. The chart reflects market confidence that its technology, which extends the action of drugs, can be used to improve existing treatments. Its value is a bet on the success of its partnerships and its own developments in CAR-T therapy.
XBIO - Share of the company's market capitalization XBIO within the market segment - Cancer cure
Xenetic Biosciences is developing the PolyXen platform to improve the pharmacological properties of existing drugs. Its market share in the biotech sector is small, but it is a technology partner. Its market capitalization reflects not its own drugs, but the potential of its technology for other companies.
Market capitalization of the market segment - Cancer cure
This chart shows the overall value of the entire oncology sector. For Xenetic Biosciences, with its platform for improving drug delivery in the blood, this line is a map of the future. The rising chart reflects investors' belief that new technologies will make existing drugs more effective and longer-acting.
Market capitalization of all companies included in a broad market index - GURU.Markets
Xenetic Biosciences is developing a platform for creating longer-lived drugs and cell therapies. Its market capitalization is the valuation of its life-extending technology for drugs. This market share is determined by fundamental innovations in drug delivery.
Book value capitalization of the company, segment and market as a whole
XBIO - Book value capitalization of the company XBIO
Xenetic Biosciences is developing the PolyXen platform to improve the performance of biologics. Its book value is derived from its intellectual property and financial resources. This represents its capital for R&D and partnerships with other pharmaceutical companies. How has this changed? The chart below shows.
XBIO - Share of the company's book capitalization XBIO within the market segment - Cancer cure
Xenetic Biosciences is a biopharmaceutical company with a platform for creating polymer-conjugated drugs. Its PolyXen technology requires a dedicated laboratory for developing and testing new drugs. The chart shows the company's share of the physical R&D infrastructure in this segment.
Market segment balance sheet capitalization - Cancer cure
Xenetic Biosciences is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Xenetic focuses on developing a drug discovery platform, and its capital is intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Xenetic Biosciences' assets are not drugs, but rather its patented PolyXen technology for enhancing the pharmacological properties of proteins and peptides, making them more durable in the body. The book value reflects this platform's potential for partnerships with other pharmaceutical companies.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - XBIO
Xenetic Biosciences is a biopharmaceutical company with a platform for improving drug delivery in the bloodstream. Its market capitalization is based on its PolyXen technology and its potential to make existing drugs more effective.
Market to book capitalization ratio in a market segment - Cancer cure
Xenetic Biosciences is a biotech company with a drug-advancement platform. Its valuation on this chart reflects its XCART cell therapy technology and its ability to partner with other pharmaceutical companies.
Market to book capitalization ratio for the market as a whole
Xenetic Biosciences is developing the PolyXen platform to improve the performance of biologics. The company's value lies in its technology, which can be applied to a wide range of drugs. This chart shows how investors value platform biotech companies with broad potential.
Debts of the company, segment and market as a whole
XBIO - Company debts XBIO
Xenetic, a biotech company with a platform for creating improved drugs, funds its R&D programs through partnerships and raised capital. This chart shows its funding strategy, which aims to validate the potential of its technology in various therapeutic areas.
Market segment debts - Cancer cure
Xenetic Biosciences is a biopharmaceutical company developing the XCART platform for personalized CAR-T cell therapy for blood cancer. This chart shows how the company is funding the clinical-stage development of its complex and expensive technology in one of the most advanced areas of oncology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio XBIO
Xenetic Biosciences is developing the PolyXen platform to improve the pharmacokinetics of proteins and peptides and is also involved in the development of CAR-T therapy. Biotech platforms require lengthy and expensive research. This chart shows how the company uses debt to fund its diverse and high-risk research programs.
Market segment debt to market segment book capitalization - Cancer cure
Xenetic Biosciences is developing a platform for creating polymers conjugated to drugs to improve their therapeutic properties, primarily in oncology. This chart shows how the biotech startup finances its research. It compares its debt structure to the overall financial landscape of the biotech sector.
Debt to book value of all companies in the market
Xenetic Biosciences is developing a platform for creating more effective biological drugs and cell therapies. Development-stage biotech companies require a constant influx of capital. What role does debt play in their survival strategy? This graph of total debt in the economy helps assess the risks associated with funding such innovations.
P/E of the company, segment and market as a whole
P/E - XBIO
Xenetic Biosciences is a biopharmaceutical company developing the PolyXen platform for enhancing the pharmacological properties of proteins and peptides. This chart shows how investors value its technology. The valuation depends on the success of the platform's application and partnerships.
P/E of the market segment - Cancer cure
Xenetic Biosciences is a biopharmaceutical company developing the XCART platform for creating personalized CAR-T cell therapy for cancer treatment. This chart illustrates the average valuation in the cell therapy sector, where investors are betting on breakthrough but high-risk approaches to oncology.
P/E of the market as a whole
Xenetic Biosciences is a biopharmaceutical company developing the XCART platform for creating personalized T-cell therapy for cancer. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether XBIO's high valuation is based on faith in its innovative platform or is driven by overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company XBIO
Xenetic Biosciences is developing the PolyXen platform to improve the pharmacokinetic properties of biologics and is also involved in the development of CAR-T therapy. This chart reflects the combined investor expectations for the success of both technology platforms and their potential for developing new drugs.
%20P%2FE%20XBIO&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-XBIO&v=1772648905741 "Chart of the company's future (projected) P/E XBIO")
Future (projected) P/E of the market segment - Cancer cure
Xenetic Biosciences is developing the PolyXen platform to improve the pharmacological properties of existing drugs and is also involved in the development of CAR-T therapy. The chart shows average profitability expectations in the sector, helping to understand how the market views this dual strategy and the potential of its technology platforms.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772648905788 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Xenetic Biosciences is developing a platform for creating polymer-conjugated drugs, particularly for cancer treatment. It's a technological platform for improving existing drugs. This biotech risk appetite chart reflects how willing investors are to invest in technologies that can improve therapeutics, rather than creating them from scratch.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772648905832 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit XBIO
Xenetic Biosciences is developing the PolyXen platform to improve the pharmacokinetic properties of biologics and is also involved in the development of CAR-T cell therapy. Financial indicators reflect R&D expenditures. This chart shows investments in technologies that can improve existing and new drugs.
Profit of companies in the market segment - Cancer cure
Xenetic Biosciences is a biopharmaceutical company developing a platform for polymer-conjugated drugs (PolyXen) and CAR-T cell therapy for cancer treatment. This chart shows overall profitability in the cancer treatment sector, where platform technologies applicable to various drugs and therapies are of particular interest to investors.
Overall market profit
Xenetic Biosciences is a biopharmaceutical company developing a platform for creating long-acting drugs. Its success depends on clinical trial results and partnerships with major pharmaceutical companies. This process is not tied to the general economic cycles seen in this chart, which is typical for the biotech sector.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company XBIO
Xenetic Biosciences is developing the PolyXen platform to improve the pharmacokinetics of biologics and is developing CAR-T cell therapy. Future revenue depends on the success of these technologies and partnerships. This chart shows analyst expectations for its diversified biotech portfolio.
%20profit%20of%20the%20company%20XBIO&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-XBIO&v=1772648906052 "Graph of future (projected) profit of the company XBIO")
Future (predicted) profit of companies in the market segment - Cancer cure
Xenetic Biosciences is developing the PolyXen platform to improve the pharmacological properties of biologics and is also involved in the development of CAR-T therapy. Its diversified approach targets various areas of biotechnology. This chart shows revenue projections for the oncology sector, providing context for evaluating Xenetic's technologies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772648906079 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Xenetic Biosciences is a biopharmaceutical company developing a platform for creating drugs with improved properties. Its success depends on partnerships and successful clinical trials. This revenue expectation schedule influences the willingness of large pharmaceutical companies and investors to invest in innovative platforms.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772648906206 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - XBIO
Xenetic Biosciences is developing the PolyXen platform to improve the pharmacokinetics of biologics. Revenue may come from partnerships. This chart shows how investors view the technology itself and its potential for creating more effective drugs in collaboration with other pharmaceutical companies.
P/S market segment - Cancer cure
Xenetic Biosciences is developing the XCART platform for creating personalized CAR-T therapy for cancer treatment. Their approach is unique in that it modifies a patient's T cells to attack tumor-specific neoantigens. This graph shows the average revenue estimate for the sector, helping to understand how the market is valuing this new generation of cell therapy.
P/S of the market as a whole
Xenetic Biosciences is developing a platform for the creation of polymer-conjugated drugs and CAR-T cell therapy. This chart highlights that the valuation of such biotech platforms depends on their potential for creating multiple products, rather than the success of a single drug, which distinguishes them from the market average.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company XBIO
Xenetic Biosciences is developing the XCART platform to create personalized T-cell therapy for cancer treatment, which could be manufactured more quickly and affordably. A future revenue valuation is critical for such an innovative company, reflecting investors' faith in its technology and its potential to make cell therapy more accessible to a wider range of patients.
%20P%2FS%20XBIO&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-XBIO&v=1772648906394 "The graph of the company's future (projected) P/S XBIO")
Future (projected) P/S of the market segment - Cancer cure
Xenetic Biosciences is a biopharmaceutical company developing the XCART platform for personalized cell therapy for cancer. This chart compares the company's estimated future sales with expectations for the biotech sector. It shows how investors view the potential of its technology for treating B-cell lymphomas and other oncological diseases.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772648906480 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Xenetic Biosciences is developing the PolyXen platform to improve the pharmacological properties of existing drugs and is also involved in the development of CAR-T cell therapy. A diversified approach mitigates risks. This graph of investor expectations reflects their view of biotechnology, where platform technologies have the potential for widespread application.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772648906550 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales XBIO
This chart shows the financial performance of Xenetic Biosciences, a biopharmaceutical company developing a platform for creating drugs with improved therapeutic properties. There is no commercial sales revenue, and income may come from royalties and partnerships based on its technology.
Sales of companies in the market segment - Cancer cure
Xenetic Biosciences is developing the PolyXen platform to improve the pharmacokinetics of biologics. Its revenue may come from licensing fees from partners using its technology. Future revenue depends on the success of its own developments in cancer cell therapy.
Overall market sales
Xenetic Biosciences is a biopharmaceutical company developing a platform for creating polymer-conjugated drugs, primarily for cancer treatment. Its success depends on research results. This overall economics chart is irrelevant for assessing the company, whose value lies in its scientific platform and the potential to create more effective drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company XBIO
Xenetic Biosciences is developing the XCART platform—a personalized CAR-T cell therapy for B-cell lymphomas that targets individual tumor antigens. Future revenues depend on the success of this technology. This graph reflects analyst expectations for the commercial potential of its highly personalized approach to cancer treatment.
%20sales%20of%20the%20company%20XBIO&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-XBIO&v=1772648906735 "Schedule of future (projected) sales of the company XBIO")
Future (projected) sales of companies in the market segment - Cancer cure
Xenetic Biosciences is developing the PolyXen platform to enhance the pharmacological properties of proteins and peptides. This chart shows sales forecasts for the biotech sector. Is demand growing for technologies that can make existing drugs more effective and long-acting? This reflects a general trend.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772648906768 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Xenetic Biosciences is a biopharmaceutical company developing a platform for creating long-acting drugs. Its value depends on the success of its technology and partnerships with major pharmaceutical companies. The general economic trends reflected in this chart do not directly impact the scientific and corporate processes that will shape Xenetic's future.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772648906771 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality XBIO
Xenetic Biosciences is developing a platform for the creation of polysaccharide conjugate drugs and CAR-T cell therapy. This chart reflects the company's financial performance at the research stage. Profitability is a long-term prospect, dependent on the success of its technological platforms and partnerships with major pharmaceutical companies for their further development.
Market segment marginality - Cancer cure
Xenetic Biosciences, Inc. is a biopharmaceutical company developing the XCART platform for personalized cell therapy for cancer. This chart reflects its financial position at the R&D stage, where profitability depends on the success of its innovative technology in preclinical and clinical trials.
Market marginality as a whole
Xenetic Biosciences develops a platform for creating more effective biological drugs and cell therapies. The company operates in the biotechnology industry, where innovation drives value. This overall return chart reflects the investment climate, which impacts the ability of companies like Xenetic to raise capital for research.
Employees in the company, segment and market as a whole
Number of employees in the company XBIO
Xenetic Biosciences is developing a platform for creating polymer-conjugated drugs, particularly for cancer treatment. Its small team of scientists is its greatest asset. This chart shows how the biotech startup manages its resources during clinical trials, where progress depends on results obtained in small patient groups.
Share of the company's employees XBIO within the market segment - Cancer cure
Xenetic Biosciences is developing a platform for the creation of polymer-conjugated drugs and CAR-T cell therapy. These are cutting-edge biotechnologies that require a team of highly qualified scientists. This graph shows the company's market share, reflecting its scientific potential and the scope of its research in two different technological areas.
Number of employees in the market segment - Cancer cure
Xenetic Biosciences is developing the PolyXen platform to improve the pharmacokinetic properties of biologics and is also involved in the development of CAR-T therapy. The chart shows its involvement in the oncology sector. The company's technologies are aimed at creating more effective and long-acting drugs.
Number of employees in the market as a whole
Xenetic Biosciences is developing a platform for creating a new generation of drugs for the treatment of cancer and autoimmune diseases. Its development depends on scientific breakthroughs. Unlike the overall labor market dynamics shown in this graph, employment at Xenetic is driven by long-term investments in R&D and the potential of its technological platform.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company XBIO (XBIO)
Xenetic Biosciences is a biotech company developing the XCART platform for cancer cell therapy. This is cutting-edge R&D. This chart shows the high speculative value the market places on their technology. It reflects the market capitalization per scientist, which is a bet on their sophisticated CAR-T platform.
%20of%20the%20company%20XBIO%20(XBIO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-XBIO-XBIO&v=1772648906970 "Chart of market capitalization per employee (in thousands of dollars) of the company XBIO (XBIO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Xenetic Biosciences (XBIO) is developing the XCART platform for creating personalized CAR-T therapy for cancer treatment. In this competitive field of oncology, this chart demonstrates how unique the market perceives their technology. A high score may indicate that their approach allows them to develop cell therapy faster and more cost-effectively than their competitors.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772648906992 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Xenetic Biosciences is developing the PolyXen platform for improving the pharmacokinetic properties of drugs. The company's valuation is based on the potential of this technology. The chart shows a high valuation per employee, as this platform could be licensed to many pharmaceutical companies to improve their own drugs, generating significant royalties.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772648907030 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company XBIO (XBIO)
Xenetic Biosciences is a biotech company developing the PolyXen platform for drug enhancement and cell therapy (CAR-T). It's an R&D company. This chart shows the investment phase. The loss per employee means that each scientist is a cost center working on licensing or technology development.
%20Chart%20XBIO%20(XBIO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-XBIO-XBIO&v=1772648907051 "Company Profit Per Employee (in thousands of dollars) Chart XBIO (XBIO)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Xenetic Biosciences, Inc. is a biopharmaceutical company developing the XCART platform for cancer cell therapy. In this high-tech field, productivity per employee reflects the potential of their scientific platform. The graph shows the financial return per team, allowing one to assess the company's stage of development compared to other players in CAR-T therapy.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772648907071 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Xenetic Biosciences is a biotech company developing the PolyXen platform to improve drug delivery. They also work in CAR-T therapy. This is an R&D business. This chart, which reflects average market profitability, demonstrates how the biotech model, with its small workforce and high stakes, differs from the rest of the economy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772648907096 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee XBIO (XBIO)
Xenetic Biosciences is developing a platform for creating more effective biological drugs. During the R&D phase, revenue per employee may be low and come from partnerships. The graph illustrates the potential: successful licensing of their technology to large pharmaceutical companies could lead to high revenue with a small staff.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-XBIO-XBIO&v=1772648907139 "Sales chart per company employee XBIO (XBIO)")
Sales per employee in the market segment - Cancer cure
Xenetic Biosciences (XBIO) is a clinical-stage biotech developing a CAR-T cell therapy platform for oncology. They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of Xenetic's R&D staff burn rate.
Sales per employee for the market as a whole
Xenetic Biosciences is a biotech company developing the PolyXen platform to improve drug delivery (for example, for cancer treatment). Their business is R&D and licensing. This chart reflects their R&D status: revenue, if any, comes from partnerships rather than from mass sales.
Short shares by company, segment and market as a whole
Shares shorted by company XBIO (XBIO)
Xenetic (XBIO) is developing a platform for creating longer-lasting drugs and CAR-T cell therapies. This chart shows the number of short positions. Bears may doubt the company's technology actually works or that it can compete in the crowded CAR-T space.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-XBIO-XBIO&v=1772648907224 "Short Shares Chart for the Company XBIO (XBIO)")
Shares shorted by market segment - Cancer cure
Xenetic Biosciences (XBIO) is a biotech company developing a platform (PolyXen) to improve the properties of existing drugs and CAR-T therapy for oncology. This chart aggregates short positions across the entire oncology biotech sector. It reflects general investor skepticism about the risks of clinical trials.
Shares shorted by the overall market
Xenetic Biosciences is a biotech platform (PolyXen) for drug improvement. It's a B2B science. This chart reflects the overall market pessimism. Investors fear that during the crisis, "big pharma" will cut R&D budgets and abandon partnerships with smaller platforms, preferring to develop their own internal projects.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator XBIO (XBIO)
Xenetic Biosciences is developing a platform (XCART) for cancer cell therapy. This is an extremely hot and speculative area. This chart is the pulse of their R&D. Investor interest "overheats" with any news about the progress of their platform or a partnership with a major pharmaceutical company.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-XBIO-XBIO&v=1772648907265 "RSI 14 indicator chart for the company's stock XBIO (XBIO)")
RSI 14 Market Segment - Cancer cure
Xenetic (XBIO) is a biotech company developing a platform (XCART) to develop CAR-T cell therapy for the treatment of B-cell cancer. This chart measures overall sentiment in the Oncology sector. It helps distinguish the success of XBIO's technology from the overall "overheating" or "overselling" of the biotech sector.
RSI 14 for the overall market
For Xenetic Biosciences (XBIO), a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast XBIO (XBIO)
Xenetic Biosciences is a biotech company developing the XCART platform for cancer cell therapy (CAR-T), as well as PolyXen technology for improved drug delivery. This chart shows the speculative average 12-month price target from analysts based on their assessment of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-XBIO-XBIO&v=1772648907366 "A chart showing analyst consensus forecasts for the expected stock price. XBIO (XBIO)")
The difference between the consensus estimate and the actual stock price XBIO (XBIO)
Xenetic Biosciences is a biotech company developing the XCART platform to create a "universal" (allogeneic) CAR-T cell therapy for cancer treatment. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their view on this risky but breakthrough R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-XBIO-XBIO&v=1772648907410 "A chart showing the difference between the consensus forecast and the actual stock price. XBIO (XBIO)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Xenetic Biosciences is an R&D biotech company developing cell therapy (CAR-T) for the treatment of blood cancers using its XCART platform. This chart reflects analysts' overall expectations for the entire cancer treatment sector. It shows whether experts believe in the success of junior R&D platforms in oncology.
Analysts' consensus forecast for the overall market share price
Xenetic Biosciences is a biotech company developing a cell therapy platform (CAR-T) for cancer. This is a high-risk sector. This chart reflects the overall market "risk appetite." For XBIO, whose value is based on future hopes, overall market optimism (a rising chart) is critical for attracting capital to fund research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index XBIO
Xenetic is a biotech (CAR-T) for blood cancer treatment that (they claim) can attack new targets (B cells). This chart is a pure indicator of their R&D. It reflects their (very long) journey, their partnerships, and the market's speculative faith in their platform technology.
AKIMA Market Segment Index - Cancer cure
Xenetic Biosciences is at the forefront of the fight against cancer, developing XCART cell therapy technology. This is one of the most complex and capital-intensive areas of biotech. How effective is their approach compared to others? This chart compares their composite index to the sector average, giving investors a benchmark for assessing their position.
The AKIM Index for the overall market
Xenetic Biosciences is a biopharmaceutical company focused on immuno-oncology (DNase technology) for the treatment of solid tumors. This chart, reflecting the market average, provides a macro backdrop. It helps assess how XBIO, a preclinical research company, compares to overall economic trends.
